Top-News

Cytrx News

Keine aktuellen Kursdaten verfügbar
WKN: A2H6Z0
ISIN: US2328286081
US-Symbol: CYTR
Typ: Aktie

Cytrx News

21.07.20 - PR Newswire
CytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
CytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-​Pick Disease Type-C ...
20.07.20 - PR Newswire
CytRx Corporation Highlights Orphazyme's Announcement of its Collaboration with The Michael J. Fox Foundation on Parkinson's Disease Research
CytRx Corporation Highlights Orphazyme's Announcement of its Collaboration with The Michael J. Fox Foundation on Parkinson's Disease Research Arimoclomol has potential ...
29.06.20 - PR Newswire
CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease
CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease Arimoclomol demonstrated a marked and clinically ...
01.06.20 - PR Newswire
CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-​Pick Disease Type-C EMA Marketing ...
26.05.20 - PR Newswire
CytRx Corporation Highlights Orphazyme's Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
CytRx Corporation Highlights Orphazyme's Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS) PR Newswire
21.05.20 - PR Newswire
CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin
CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin Partner ImmunityBio Inc. Announces the Initiation of a Phase 2 Registrational-​Intent Study ...
29.04.20 - PR Newswire
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-​Pick Disease CytRx Eligible to Receive up to $120 Million in Future ...
10.03.20 - PR Newswire
CytRx Corporation Provides Update on Management Change
CytRx Corporation Provides Update on Management Change PR Newswire
28.02.20 - PR Newswire
CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S
CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S PR Newswire
11.02.20 - PR Newswire
CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM)
CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM) ...
29.01.20 - PR Newswire
CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin
CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin CytRx Licensee ImmunityBio, Previously NantCell, Inc., Announced Complete ...
19.12.19 - PR Newswire
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin CytRx Licensee Orphazyme A/S Granted Breakthrough ...
09.08.19 - PR Newswire
CytRx Corporation Reports Second Quarter 2019 Financial Results
CytRx Corporation Reports Second Quarter 2019 Financial Results Licensee Orphazyme A/S Rapidly Completes Enrollment in Clinical Trials for Multiple Indications and Prepares ...
30.07.19 - PR Newswire
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-​Pick Disease Type C Orphazyme to File both ...
26.06.19 - PR Newswire
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation Patent Covers the Formulation, Storage, Delivery and Administration of Aldoxorubicin at Room ...
19.06.19 - PR Newswire
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-​Pick Disease Type C Expected Submission of ...
31.05.19 - PR Newswire
CytRx Corporation to Commence Trading on OTCQB Venture Market
CytRx Corporation to Commence Trading on OTCQB Venture Market Company to Continue Trading Under Ticker Symbol "CYTR" PR Newswire
15.05.19 - PR Newswire
CytRx Corporation Reports First Quarter 2019 Financial Results
CytRx Corporation Reports First Quarter 2019 Financial Results Out-​licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need ...
08.05.19 - PR Newswire
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer The Patent Covers the Use of Aldoxorubicin Intravenously, Intra-​Arterially or ...
02.05.19 - PR Newswire
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus ...

Newssuche

Videos

newspaper
18.04.24
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »